Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited develops treatments for neurodegenerative diseases, with a clinical program centered on Multiple System Atrophy and related Parkinsonian disorders. News about ATHE commonly covers ATH434, its lead MSA candidate, Phase 2 analyses, FDA interactions, chemistry, manufacturing and control updates, and presentations at neurology and imaging conferences.
Coverage also includes bioMUSE Natural History Study biomarker work, including quantitative susceptibility mapping MRI for iron dysregulation in MSA, Appendix 4C cash flow and corporate updates, board appointments, and discussions of the company’s drug discovery platform for patentable chemical compounds targeting neurological disease pathology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced findings from the bioMUSE study at the American Academy of Neurology Annual Meeting, showcasing wearable sensors' effectiveness in quantifying motor impairment in patients with Multiple System Atrophy (MSA). The analysis involved 17 participants and indicated a strong correlation between sensor parameters and traditional clinical assessments of motor impairment. This data is significant for future clinical trials, as wearable sensors will be integrated as secondary endpoints in the ongoing Phase 2 trial of ATH434. ATH434 aims to address neurodegeneration and has shown promise in preclinical studies. The ongoing research is pivotal for understanding MSA's progression and optimizing treatment methods.
Alterity Therapeutics (ATHE) has initiated its Phase 2 clinical trial for ATH434 in the UK, targeting Multiple System Atrophy (MSA), a rare neurodegenerative disorder. This trial is a randomized, double-blind, placebo-controlled study intended to evaluate ATH434's effects on neuroimaging and protein biomarkers. With the first UK participant dosed, the trial aims to enroll approximately 60 adults over 12 months, focusing on efficacy and safety. ATH434 has shown preclinical promise and is acknowledged with Orphan designation by the U.S. FDA and European Commission for MSA treatment, indicating significant therapeutic potential for this debilitating condition.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the dosing of the first participant in its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) on March 16, 2023. This pivotal trial is being conducted at Vanderbilt University Medical Center and will involve approximately 60 adults. The study is designed to evaluate the effect of ATH434 on neuroimaging and biomarkers specific to MSA pathology, along with safety and efficacy measures. ATH434 aims to inhibit pathological protein aggregation and has shown promise in preclinical studies. The trial is critical for developing a potential treatment option for the 15,000 individuals living with MSA in the U.S.